Emergent BioSolutions' (EBS) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Emergent BioSolutions (NYSE:EBS - Free Report) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $15.00 target price on the biopharmaceutical company's stock.

EBS has been the topic of several other research reports. Rodman & Renshaw reissued a "buy" rating and set a $16.00 price target on shares of Emergent BioSolutions in a research report on Friday, September 13th. Benchmark lifted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Finally, StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Saturday, December 28th.

Emergent BioSolutions Price Performance

EBS traded down $0.22 during trading on Friday, reaching $9.87. The company's stock had a trading volume of 949,567 shares, compared to its average volume of 1,042,061. The company has a market cap of $534.76 million, a price-to-earnings ratio of -2.41 and a beta of 1.59. The firm has a fifty day simple moving average of $9.33 and a two-hundred day simple moving average of $9.08. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.

Hedge Funds Weigh In On Emergent BioSolutions

A number of hedge funds and other institutional investors have recently bought and sold shares of EBS. State Street Corp grew its holdings in shares of Emergent BioSolutions by 864.7% in the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company's stock valued at $15,960,000 after purchasing an additional 1,713,200 shares in the last quarter. Oak Hill Advisors LP acquired a new position in Emergent BioSolutions during the 3rd quarter worth $9,296,000. Millennium Management LLC increased its holdings in Emergent BioSolutions by 5.8% during the 2nd quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company's stock worth $6,454,000 after purchasing an additional 52,144 shares during the period. American Century Companies Inc. boosted its stake in shares of Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company's stock valued at $6,015,000 after buying an additional 623,201 shares during the period. Finally, Assenagon Asset Management S.A. increased its stake in shares of Emergent BioSolutions by 74.5% during the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company's stock worth $6,192,000 after buying an additional 316,700 shares during the period. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.